组织病理学引导下钌-106 敷贴器近距离放射治疗角膜基质或巩膜侵袭性眼表鳞状上皮瘤
这项回顾性、非对照、干预性病例系列纳入 42 只经组织病理学证实角膜基质和/或巩膜侵袭的眼表鳞状上皮瘤眼,在 4 mm 临床清晰切缘切除后行钌-106 表面敷贴器近距离放射治疗,总剂量 5000 cGy 至轴向深度 2 mm。平均随访 36.9 个月,全部 42 只眼(100%)实现完全肿瘤消退,2 只眼(5%)出现远隔结膜肿瘤生长,无区域淋巴结或全身转移证据。
要点
- 42 只眼经组织病理学证实角膜基质和/或巩膜侵袭的眼表鳞状上皮瘤,切除后接受钌-106 表面敷贴器近距离放射治疗。
- 平均随访 36.9 个月,完全肿瘤消退率为 100%(42/42 只眼),2 只眼(5%)出现远隔结膜肿瘤生长。
- 35 只眼(83%)视力维持 ≥20/200,1 只眼(2%)视力下降超过 2 行 Snellen 视力表,无区域淋巴结或全身转移。
核心结论
- 组织病理学引导下使用钌-106 表面敷贴器近距离放射治疗是管理眼表鳞状上皮瘤角膜基质和/或巩膜侵袭的安全且有效的辅助治疗。
研究设计与样本
- 回顾性、非对照、干预性病例系列,纳入 42 只经组织病理学证实角膜基质和/或巩膜侵袭的眼表鳞状上皮瘤眼。
- 治疗为切除后行钌-106 表面敷贴器近距离放射治疗,总剂量 5000 cGy,平均治疗时长 19.7 小时(范围 7-41 小时),至轴向深度 2 mm。
- 治疗前 2 例(5%)曾行切除活检,1 例(2%)曾行切开活检,1 例(2%)曾行局部干扰素治疗。
主要发现
- 初诊时平均肿瘤基底直径 9.3 mm(范围 5-26 mm),厚度 3.1 mm(范围 1.5-11 mm)。
- 平均随访 36.9 个月(范围 22.3-72 个月),全部 42 只眼(100%)实现完全肿瘤消退。
- 2 只眼(5%)出现远隔于既往治疗部位的结膜肿瘤生长。
- 35 只眼(83%)视力维持 ≥20/200,1 只眼(2%)视力下降超过 2 行 Snellen 视力表。
- 无区域淋巴结或全身转移证据。
临床怎么用
- 原文结论认为组织病理学引导下钌-106 表面敷贴器近距离放射治疗是管理眼表鳞状上皮瘤角膜基质和/或巩膜侵袭的安全且有效的辅助治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIM: To evaluate the safety and efficacy of ruthenium-106 (Ru-106) plaque brachytherapy in managing invasive ocular surface squamous neoplasia (OSSN). METHODS: This is a retrospective, non-comparative, interventional case series of 42 eyes with OSSN with histopathologically-proven corneal stromal and/or scleral invasion that underwent Ru-106 plaque brachytherapy. Main outcome measures were tumour regression, eye salvage, final visual acuity, treatment complications and metastasis. RESULTS: At presentation, the mean tumour basal diameter was 9.3 mm (range 5-26 mm) and thickness 3.1 mm (range 1.5-11 mm). Prior treatment included excision biopsy in two patients (5%), incision biopsy and topical interferon in one each (2%). Following excision with 4 mm clinically clear margins, corneal stromal and/or scleral invasion of OSSN was confirmed in all 42 cases, with the excised base showing invasive squamous cell carcinoma. A total dose of 5000 cGy over a mean duration of 19.7 hours (range 7-41 hours) was provided to an axial depth of 2 mm using Ru-106 surface plaque. Over a mean follow-up of 36.9 months (range 22.3-72 months), complete tumour regression was achieved in all eyes (100%). Two eyes (5%) showed conjunctival tumour growth remote from the site of prior treatment. Visual acuity was maintained at ≥20/200 in 35 eyes (83%), with a loss of >2 Snellen lines in 1 eye (2%). There was no evidence of regional lymph node or systemic metastasis. CONCLUSION: Histopathology-guided use of Ru-106 surface plaque brachytherapy is a safe and an effective adjuvant therapy in the management of corneal stromal and/or scleral invasion of OSSN.
引用
- Rao R, Honavar SG, Lahane S, et al. Histopathology-guided management of ocular surface squamous neoplasia with corneal stromal or scleral invasion using ruthenium-106 plaque brachytherapy. Br J Ophthalmol. 2021. PMID: 34844918. doi:10.1136/bjophthalmol-2021-319201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。